Company intelligence / Profile preview
Eigen Therapeutics
Redwood City, California, United Stateseigentx.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Eigen Therapeutics is developing a platform for "priming" cancer cells—making them more visible to targeted cancer treatments. Their approach aims to address tumor heterogeneity by increasing the expression of therapeutic targets on cancer cells before administering targeted agents. The company is currently in preclinical development with initial programs focused on blood cancers; no clinical results have been reported yet[4][5].
- Therapeutic areas
- OncologyHematology
- Modalities
- Priming therapies (modulate target expression)Combination therapiesTargeted therapies (including antibody-drug conjugates, radioligand therapies, CAR T-cell therapies)[1][5]
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
No major pharmaceutical or biotech partnerships publicly disclosed as of May 2025.
Beyond the preview
Go deeper on Eigen Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Eigen Therapeutics.